secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001493152-24-028081
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged
--------------------------------------------------------------------------------

- JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.
- Heme Foundation pledges up to $10M over project; $2M already invested in prototypes and compounds.
- Total development cost estimated $20M-$25M over 3.5 to 5 years; Bioxytran retains IP.
- Two successful small animal trials (mice, rabbits) completed; large 14-day toxicology study planned.
- UOC compatible with all blood types, shelf-stable 5+ years, 18-hour half-life, no known side effects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315224028081/0001493152-24-028081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315224028081/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer